Tenax Therapeutics, Inc. (TENX) financial statements (2021 and earlier)

Company profile

Business Address ONE COPLEY PARKWAY
MORRISVILLE, NC 27560
State of Incorp. DE
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments579111356
Cash and cash equivalents578101234
Short-term investments0011023
Receivables      0
Prepaid expense1010000
Total current assets:689111357
Noncurrent Assets
Operating lease, right-of-use asset0000
Property, plant and equipment0000000
Long-term investments and receivables     00
Long-term investments     00
Other noncurrent assets0000000
Total noncurrent assets:0000000
TOTAL ASSETS:6810111357
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3111201
Accounts payable2001100
Accrued liabilities1100101
Other undisclosed current liabilities     00
Total current liabilities:3111211
Noncurrent Liabilities
Long-term debt and lease obligation0000   
Operating lease, liability0000
Total noncurrent liabilities:0000   
Total liabilities:3111211
Stockholders' equity
Stockholders' equity attributable to parent, including:479101256
Preferred stock 000   
Common stock0000000
Additional paid in capital240240240240240223223
Accumulated other comprehensive income (loss)00000(0)(0)
Accumulated deficit(236)(233)(231)(229)(228)(218)(217)
Other undisclosed stockholders' equity attributable to parent0   0  
Total stockholders' equity:479101256
TOTAL LIABILITIES AND EQUITY:6810111357

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(14)222(12)22
Operating income (loss):(14)222(12)22
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
0(0)(0)(0)0(0)(0)
Net income (loss):(14)222(11)22
Other undisclosed net loss attributable to parent    (7)  
Net income (loss) available to common stockholders, diluted:(14)222(19)22

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(14)222(11)22
Comprehensive income (loss):(14)222(11)22
Other undisclosed comprehensive income (loss), net of tax, attributable to parent170(0)(0)21(0)(0)
Comprehensive income, net of tax, attributable to parent:32221022

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: